Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females 12 - 75 years of age with a diagnosis of persistent asthma
Daily treatment with a bronchodilator and daily dose of at least 100 µg beclomethasone dipropionate or equivalent
FEV1 at Visit 1 at least 50% of the predicted normal value
FEV1 reversibility at least 15%
You may not be if
Use of tobacco products within 6 months prior to Visit 1 or a smoking history of more than 10 pack years
Chronic Obstructive Pulmonary Disease (COPD)
Seasonal allergy where asthma is likely to deteriorate during the period of the study
Emergency room treatment for an acute asthma attack within the previous 6 weeks or hospitalized within the previous 6 months
Clareo Health | Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
